Cellular Therapeutics (United Kingdom)

Recent papers from Cellular Therapeutics (United Kingdom)

1. Nutrient availability shapes tumour adaptation: a systems-level view in 3D lung adenocarcinoma modelsJournal of Experimental & Clinical Cancer Research · 2026
2. TRIM23 prevents adenovirus replication by p62-mediated selective autophagic degradation of viral E1A proteinPLoS Pathogens · 2026
3. Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a reviewFrontiers in Pharmacology · 2026
4. BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US PhysiciansAdvances in Therapy · 2026
5. Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia – real-world analysis of Polish adult leukemia study groupLeukemia & lymphoma/Leukemia and lymphoma · 2026
6. Thermophysical Properties of a tRNA IsodecoderThe Journal of Physical Chemistry B · 2026
7. LUHMES-derived 3D organoids as an enhanced platform for modelling dopaminergic neurodegeneration in Parkinson's diseaseFrontiers in Molecular Biosciences · 2026
8. Severe Veno-Occlusive Disease in a Child With Wilms Tumor: Acute Management and Subsequent Bridging With Irinotecan TreatmentJournal of Pediatric Hematology/Oncology · 2026
9. Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia veraLeukemia & lymphoma/Leukemia and lymphoma · 2026
10. PhiKan 083 Inhibits MYCN Expression in Liver Cancer Cells Independent of p53 PathwaysACS Pharmacology & Translational Science · 2026
11. Cancer prevalence in the United States: trends and sociodemographic disparities based on national health interview survey data (2019–2023)Frontiers in Oncology · 2026
12. Bis-Tetrazine Fluorogenic (Silicon)-Rhodamine Dyes for Live-Cell LabelingJournal of the American Chemical Society · 2026
13. Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic centerFrontiers in Oncology · 2026
14. A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemiaBone Marrow Transplantation · 2026
15. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelJournal of Clinical Oncology · 2026
16. Real‐Time in Vivo Monitoring of Circulating Endometrial Cells: Uncovering Systemic Dissemination and Temporal Fluctuations in EndometriosisAdvanced Science · 2026
17. Galectin-3 Regulates Smooth Muscle Contraction and Blood Pressure by Modulating Ca V 1.2 Channel FunctionCirculation · 2026
18. Neutralizing LFA-1 alleviates acute lung injury by diminishing pulmonary retention of CAR-T cellsPharmacological Research · 2026
19. Management of Bispecific Antibody Toxicities: A Focus on Multiple MyelomaAmerican Society of Clinical Oncology Educational Book · 2026
20. Investigating the diversity of intratumoral microbiota in high-grade serous ovarian cancer with varying platinum sensitivityFrontiers in Cellular and Infection Microbiology · 2026